Market Overview:
HER2 inhibitors are a type of targeted drug therapy used to treat certain types of non-small cell lung cancer (NSCLC). These drugs work by blocking the HER2 protein, which helps tumors grow and spread. There are several different HER2 inhibitors available, including afatinib (Gilotrif), trastuzumab (Herceptin), and pertuzumab (Perjeta). The global market for HER2 inhibitors for NSCLC is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market is primarily driven by the increasing incidence of NSCLC, rising awareness about targeted therapies, and the launch of new products. The squamous cell carcinoma segment is expected to be the fastest-growing segment during the forecast period. Geographically, North America dominates the global market for HER2 inhibitors for NSCLC due to high prevalence of NSCLC and early adoption of novel therapies in this region.
Product Definition:
Targeted drug HER2 inhibitors are a type of medication that is used to treat certain types of cancer, including non-small cell lung cancer (NSCLC). These inhibitors work by blocking the activity of a protein called HER2, which can help to slow or stop the growth of cancer cells.
Afatinib:
Afatinib is a novel oral targeted HER2 inhibitor. It is an FDA-approved drug for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who are receiving treatment with chemotherapy and who have developed resistance to prior therapy. Afatinib’s mechanism of action as a targeted HER2 inhibitor involves targeting the Herceptin binding protein, which results in increased levels of free Herceptin that can then enter cells and inhibit tumor growth.
Trastuzumab:
Trastuzumab (Herceptin) is a humanized monoclonal antibody that targets the HER2 protein. It works by blocking the activity of the receptor, which then interferes with cell growth and division. This drug is approved for treatment of patients with advanced HER2-positive non-small cell lung cancer (NSCLC).
Application Insights:
The squamous cell carcinoma of lung cancer application segment held the largest share in 2017. This is due to the availability of approved products for this indication and increasing incidence rates. The most commonly used therapy for SCCLN is still chemotherapy, which has been experiencing resistance from various sources such as tumor cells, stromal cells, and blood vessels resulting in failure of treatment with conventional chemotherapeutic drugs.
Adenocarcinoma of lung cancer application segment is expected to witness lucrative growth during the forecast period owing to rising approval for targeted therapies including Afatinib (ZD1839), Iressa (Gemzar), Nivolumab (Opdivo), and Bezlotoxumab (Ebixa) among others. These are highly effective against this type of tumor as compared to other treatments such as surgery or radiotherapy that have limited applications due to their high costs or low success rates respectively.
Regional Analysis:
North America dominated the global market in 2017. This is due to the high incidence of NSCLC, rising adoption of targeted therapy and increasing government initiatives for cancer research. For instance, in 2014, the National Cancer Institute (NCI) launched a strategic initiative to accelerate progress against cancer by investing in basic cancer research and developing new ways to treat advanced cancers. The NCI’s comprehensive strategy focuses on four major areas: 1) Discovery; 2) Development & evaluation; 3) Improving patient care; 4) Prevention & Early Detection (PED).
Asia Pacific is expected to be one of the fastest-growing regional markets during the forecast period owing to improving healthcare infrastructure and economic development coupled with an increase in disposable income levels that enable people opt for expensive treatment options over cheaper ones.
Growth Factors:
- Increasing incidence of NSCLC: The global incidence of NSCLC is increasing rapidly and is expected to grow at a CAGR of more than 6% from 2016 to 2024. This will create a high demand for targeted drug HER2 inhibitors for NSCLC treatment.
- Rising awareness about early diagnosis and treatment: There is an increasing awareness among people about the importance of early diagnosis and treatment for cancer patients. This will drive the demand for targeted drug HER2 inhibitors for NSCLC therapy.
- Growing number of clinical trials: A growing number of clinical trials are being conducted on targeted drug HER2 inhibitors for NSCLC therapy, which is resulting in the development of better drugs with improved efficacy and safety profiles. This will boost the growth prospects of this market in the coming years.
- Technological advancements: The technological advancements in cancer detection and treatment are providing new opportunities for players operating in this market space, thereby propelling its growth trajectory further forward.. 5 Emerging markets offer immense potential: The emerging markets offer immense potential owing to their large population base and rising income levels, which are fuelling the demandfor better healthcare facilities including advanced cancer treatments such as targeted drug HER2 inhibitorsforNSLC
Scope Of The Report
Report Attributes
Report Details
Report Title
Targeted Drug HER2 Inhibitors for NSCLC Market Research Report
By Type
Afatinib, Trastuzumab, Other
By Application
Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC
By Companies
Boehringer-Ingelheim, Roche, Mylan, Biocon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
133
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Targeted Drug HER2 Inhibitors for NSCLC Market Report Segments:
The global Targeted Drug HER2 Inhibitors for NSCLC market is segmented on the basis of:
Types
Afatinib, Trastuzumab, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer-Ingelheim
- Roche
- Mylan
- Biocon
Highlights of The Targeted Drug HER2 Inhibitors for NSCLC Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Afatinib
- Trastuzumab
- Other
- By Application:
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Targeted Drug HER2 Inhibitors for NSCLC Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Targeted drug HER2 inhibitors are medications that block the growth of cancer cells that overexpress the HER2 protein. These drugs can be used to treat advanced non-small cell lung cancer (NSCLC).
Some of the key players operating in the targeted drug her2 inhibitors for nsclc market are Boehringer-Ingelheim, Roche, Mylan, Biocon.
The targeted drug her2 inhibitors for nsclc market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Targeted Drug HER2 Inhibitors for NSCLC Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Targeted Drug HER2 Inhibitors for NSCLC Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Targeted Drug HER2 Inhibitors for NSCLC Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Targeted Drug HER2 Inhibitors for NSCLC Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size & Forecast, 2018-2028
4.5.1 Targeted Drug HER2 Inhibitors for NSCLC Market Size and Y-o-Y Growth
4.5.2 Targeted Drug HER2 Inhibitors for NSCLC Market Absolute $ Opportunity
Chapter 5 Global Targeted Drug HER2 Inhibitors for NSCLC Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Type
5.2.1 Afatinib
5.2.2 Trastuzumab
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Targeted Drug HER2 Inhibitors for NSCLC Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Applications
6.2.1 Squamous Cell Carcinoma of NSCLC
6.2.2 Adenocarcinoma of NSCLC
6.2.3 Large Cell Carcinoma of NSCLC
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Targeted Drug HER2 Inhibitors for NSCLC Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Targeted Drug HER2 Inhibitors for NSCLC Analysis and Forecast
9.1 Introduction
9.2 North America Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Type
9.6.1 Afatinib
9.6.2 Trastuzumab
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Applications
9.10.1 Squamous Cell Carcinoma of NSCLC
9.10.2 Adenocarcinoma of NSCLC
9.10.3 Large Cell Carcinoma of NSCLC
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Targeted Drug HER2 Inhibitors for NSCLC Analysis and Forecast
10.1 Introduction
10.2 Europe Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Type
10.6.1 Afatinib
10.6.2 Trastuzumab
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Applications
10.10.1 Squamous Cell Carcinoma of NSCLC
10.10.2 Adenocarcinoma of NSCLC
10.10.3 Large Cell Carcinoma of NSCLC
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Targeted Drug HER2 Inhibitors for NSCLC Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Type
11.6.1 Afatinib
11.6.2 Trastuzumab
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Applications
11.10.1 Squamous Cell Carcinoma of NSCLC
11.10.2 Adenocarcinoma of NSCLC
11.10.3 Large Cell Carcinoma of NSCLC
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Targeted Drug HER2 Inhibitors for NSCLC Analysis and Forecast
12.1 Introduction
12.2 Latin America Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Type
12.6.1 Afatinib
12.6.2 Trastuzumab
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Applications
12.10.1 Squamous Cell Carcinoma of NSCLC
12.10.2 Adenocarcinoma of NSCLC
12.10.3 Large Cell Carcinoma of NSCLC
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Targeted Drug HER2 Inhibitors for NSCLC Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Type
13.6.1 Afatinib
13.6.2 Trastuzumab
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast by Applications
13.10.1 Squamous Cell Carcinoma of NSCLC
13.10.2 Adenocarcinoma of NSCLC
13.10.3 Large Cell Carcinoma of NSCLC
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Targeted Drug HER2 Inhibitors for NSCLC Market: Competitive Dashboard
14.2 Global Targeted Drug HER2 Inhibitors for NSCLC Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Boehringer-Ingelheim
14.3.2 Roche
14.3.3 Mylan
14.3.4 Biocon
